Future microbiologyPub Date : 2024-02-01Epub Date: 2023-11-07DOI: 10.2217/fmb-2023-0051
Quezia Damaris Jones Severino Vasconcelos, Marisa Jadna Silva Frederico, Renata de Sousa Alves, Tereza de Jesus Pinheiro Gomes Bandeira, Maria Elisabete Amaral de Moraes, Gislei Frota Aragão
{"title":"Effects of whey protein supplementation on gut microbiota of Wistar rats with valproic acid-induced autism symptoms.","authors":"Quezia Damaris Jones Severino Vasconcelos, Marisa Jadna Silva Frederico, Renata de Sousa Alves, Tereza de Jesus Pinheiro Gomes Bandeira, Maria Elisabete Amaral de Moraes, Gislei Frota Aragão","doi":"10.2217/fmb-2023-0051","DOIUrl":"10.2217/fmb-2023-0051","url":null,"abstract":"<p><p><b>Aim:</b> To evaluate the effects of whey protein (WP) supplementation (1.24 mg/g, 24 days) in rats with autism spectrum disorder (ASD) induced by valproic acid (400 mg/kg, single dose). <b>Materials & methods:</b> Wistar rats (14 days old) were divided into four groups: control, ASD, ASD plus WP and WP. <b>Results:</b> WP increased bacterial diversity and the number of colonies. Bacteria from the Firmicutes phylum were predominantly found in the supplemented groups (p < 0.05). WP also improved the animals' memory in the Y-maze test and decreased the time that male animals spent in the 'solitary chamber' (p < 0.05). <b>Conclusion:</b> WP supplementation positively influenced gut microbiota, along with memory.</p>","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":" ","pages":"213-226"},"PeriodicalIF":3.1,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71480814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future microbiologyPub Date : 2024-02-01Epub Date: 2024-02-08DOI: 10.2217/fmb-2023-0070
Gleyce Ha de Souza, Marcia Sm Vaz, Joyce A Dos Santos Radai, Thiago L Fraga, Luana Rossato, Simone Simionatto
{"title":"Synergistic interaction of polymyxin B with carvacrol: antimicrobial strategy against polymyxin-resistant <i>Klebsiella pneumoniae</i>.","authors":"Gleyce Ha de Souza, Marcia Sm Vaz, Joyce A Dos Santos Radai, Thiago L Fraga, Luana Rossato, Simone Simionatto","doi":"10.2217/fmb-2023-0070","DOIUrl":"10.2217/fmb-2023-0070","url":null,"abstract":"<p><p><b>Objective:</b> The antimicrobial activities of the synergistic combination of carvacrol and polymyxin B against polymyxin-resistant <i>Klebsiella pneumoniae</i> were evaluated. <b>Methods:</b> The methods employed checkerboard assays to investigate synergism, biofilm inhibition assessment and membrane integrity assay. In addition, the study included <i>in vivo</i> evaluation using a mouse infection model. <b>Results:</b> The checkerboard method evaluated 48 combinations, with 23 indicating synergistic action. Among these, carvacrol 10 mg/kg plus polymyxin B 2 mg/kg exhibited <i>in vivo</i> antimicrobial activity in a mouse model of infection, resulting in increased survival and a significant decrease in bacterial load in the blood. <b>Conclusion:</b> Polymyxin in synergy with carvacrol represents a promising alternative to be explored in the development of new antimicrobials.</p>","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":" ","pages":"181-193"},"PeriodicalIF":3.1,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139702297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future microbiologyPub Date : 2024-01-01Epub Date: 2024-03-01DOI: 10.2217/fmb-2023-0248
Sarah M McLeod, John P O'Donnell, Navaneeth Narayanan, John P Mills, Keith S Kaye
{"title":"Sulbactam-durlobactam: a β-lactam/β-lactamase inhibitor combination targeting <i>Acinetobacter baumannii</i>.","authors":"Sarah M McLeod, John P O'Donnell, Navaneeth Narayanan, John P Mills, Keith S Kaye","doi":"10.2217/fmb-2023-0248","DOIUrl":"10.2217/fmb-2023-0248","url":null,"abstract":"<p><p>Sulbactam-durlobactam is a pathogen-targeted β-lactam/β-lactamase inhibitor combination that has been approved by the US FDA for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible isolates of <i>Acinetobacter baumannii-calcoaceticus</i> complex (ABC) in patients 18 years of age and older. Sulbactam is a penicillin derivative with antibacterial activity against <i>Acinetobacter</i> but is prone to hydrolysis by β-lactamases encoded by contemporary isolates. Durlobactam is a diazabicyclooctane β-lactamase inhibitor with activity against Ambler classes A, C and D serine β-lactamases that restores sulbactam activity both <i>in vitro</i> and <i>in vivo</i> against multidrug-resistant ABC. Sulbactam-durlobactam is a promising alternative therapy for the treatment of serious <i>Acinetobacter</i> infections, which can have high rates of mortality.</p>","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":" ","pages":"563-576"},"PeriodicalIF":2.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11229585/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139996042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Establishment and evaluation of MIRA-qPCR assay for the rapid and sensitively detection of <i>Mycoplasma pneumoniae</i>.","authors":"Qiao Qiao, Yi-Yue Ge, Xiao-Juan Zhu, Kang-Chen Zhao, Yin Chen, Lun-Biao Cui, Tao Wu","doi":"10.1080/17460913.2024.2398886","DOIUrl":"10.1080/17460913.2024.2398886","url":null,"abstract":"<p><p><b>Aim:</b> <i>Mycoplasma pneumoniae</i> (MP) is a common cause of respiratory infections, and its incidence has increased post-COVID-19 due to \"immune debt.\" Real-time quantitative polymerase chain reaction (qPCR) is the standard for detecting MP, but it has a lengthy detection time. This study aimed to establish a highly sensitive rapid detection method for MP.<b>Materials & methods:</b> We developed an integrated assay combining multienzyme isothermal rapid amplification (MIRA) with qPCR, referred to as MIRA-qPCR, for the rapid detection of MP, delivering results within approximately 40 min.<b>Results:</b> The analytic sensitivity of the MIRA-qPCR assay was 10 copies per reaction, and it exhibited no cross-reactivity with other respiratory pathogens, ensuring high specificity. Clinical sample analysis demonstrated higher sensitivity for MIRA-qPCR compared to qPCR reported in the literature, and 100% concordance with commercial qPCR kit.<b>Conclusion:</b> The MIRA-qPCR method established in this study is a promising tool for the clinical detection of MP, offering significant advantages for the rapid diagnosis of MP infections.</p>","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":" ","pages":"1455-1461"},"PeriodicalIF":2.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11492641/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142284402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future microbiologyPub Date : 2024-01-01Epub Date: 2024-01-31DOI: 10.2217/fmb-2023-0160
Francisca B Stefany Aires do Nascimento, Lívia Gurgel do Amaral Valente Sá, João B de Andrade Neto, Lisandra Juvêncio da Silva, Daniel Sampaio Rodrigues, Vitória P de Farias Cabral, Amanda Dias Barbosa, Lara E Almeida Moreira, Camille R Braga Vasconcelos, Bruno Coêlho Cavalcanti, Maria E França Rios, Jacilene Silva, Emmanuel Silva Marinho, Helcio Silva Dos Santos, Jacó Rl de Mesquita, Marina Duarte Pinto Lobo, Manoel Odorico de Moraes, Hélio V Nobre Júnior, Cecília Rocha da Silva
{"title":"Antimicrobial activity of hydralazine against methicillin-resistant and methicillin-susceptible <i>Staphylococcus aureus</i>.","authors":"Francisca B Stefany Aires do Nascimento, Lívia Gurgel do Amaral Valente Sá, João B de Andrade Neto, Lisandra Juvêncio da Silva, Daniel Sampaio Rodrigues, Vitória P de Farias Cabral, Amanda Dias Barbosa, Lara E Almeida Moreira, Camille R Braga Vasconcelos, Bruno Coêlho Cavalcanti, Maria E França Rios, Jacilene Silva, Emmanuel Silva Marinho, Helcio Silva Dos Santos, Jacó Rl de Mesquita, Marina Duarte Pinto Lobo, Manoel Odorico de Moraes, Hélio V Nobre Júnior, Cecília Rocha da Silva","doi":"10.2217/fmb-2023-0160","DOIUrl":"10.2217/fmb-2023-0160","url":null,"abstract":"<p><p><b>Background:</b> <i>Staphylococcus aureus</i> is a human pathogen responsible for high mortality rates. The development of new antimicrobials is urgent. <b>Materials & methods:</b> The authors evaluated the activity of hydralazine along with its synergism with other drugs and action on biofilms. With regard to action mechanisms, the authors evaluated cell viability, DNA damage and molecular docking. <b>Results:</b> MIC and minimum bactericidal concentration values ranged from 128 to 2048 μg/ml. There was synergism with oxacillin (50%) and vancomycin (25%). Hydralazine reduced the viability of biofilms by 50%. After exposure to hydralazine 2× MIC, 58.78% of the cells were unviable, 62.07% were TUNEL positive and 27.03% presented damage in the comet assay (p < 0.05). Hydralazine showed affinity for DNA gyrase and TyrRS. <b>Conclusion:</b> Hydralazine is a potential antibacterial.</p>","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":" ","pages":"91-106"},"PeriodicalIF":3.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139641960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future microbiologyPub Date : 2024-01-01Epub Date: 2024-10-17DOI: 10.1080/17460913.2024.2408136
Zimeng You, Yaling Dai, Yuping Ran
{"title":"Clioquinol influences cell membrane, attenuates virulence factors, induces apoptosis to inhibit <i>Candida albicans</i> growth.","authors":"Zimeng You, Yaling Dai, Yuping Ran","doi":"10.1080/17460913.2024.2408136","DOIUrl":"10.1080/17460913.2024.2408136","url":null,"abstract":"<p><p><b>Aim:</b> To investigate the antifungal mechanism of clioquinol and indicate that clioquinol has potential as a novel therapeutic antifungal agent.<b>Materials & methods:</b> Analyze differentially expressed genes of <i>Candida albicans</i> treated with clioquinol using RNA-sequencing. The effects on cell wall and membrane features, virulence factors, apoptosis-induced cell death were also investigated.<b>Results:</b> The differentially expressed genes of <i>C. albicans</i> after treated with clioquinol focused on cell wall and membrane synthesis, antioxidant system and energy metabolism. Clioquinol did not change cell wall components levels while it decreased squalene epoxidase activity to influence the ergosterol biosynthesis in cell membrane. It also decreased cellular surface hydrophobicity and induced β-glucan unmasking to attenuate virulence factors. Meanwhile, clioquinol influenced enzyme activities involved in antioxidant system, citrate cycle, oxidative phosphorylation and decreased the ATP levels. Clioquinol induced apoptosis in <i>C. albicans</i> to exert its fungicidal activity. It induced reactive oxygen species and calcium ion elevation, leading to loss of mitochondrial membrane potential, cytochrome C release, metacaspase activation, thereby triggering apoptosis.<b>Conclusion:</b> Clioquinol exerted anti-<i>C. albicans</i> activity through influencing cell membrane, attenuating virulence factors and inducing apoptosis.</p>","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":" ","pages":"1545-1557"},"PeriodicalIF":2.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142463282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Effect of amikacin-humic acid combination on <i>Acinetobacter baumannii</i> biofilm: an <i>in vitro</i> and <i>in silico</i> study.","authors":"Seetha Lakshmi Rajangam, Kakithakara Vajravelu Leela, Manonmoney Jayaraman, Sarvesh Sabarathinam, Manoj Kumar Narasimhan","doi":"10.1080/17460913.2024.2412431","DOIUrl":"10.1080/17460913.2024.2412431","url":null,"abstract":"<p><p><b>Aim:</b> <i>Acinetobacter baumannii</i> (AB) is a clinically important bacterial pathogen responsible for nosocomial infections. The biofilm-forming capability of these pathogens reduces the antibiotic penetration and its efficacy, thereby complicating the treatment. The current work aims to isolate the most potent biofilm-forming <i>Acinetobacter</i> species from clinical isolates of the patient samples and to evaluate the efficacy of the amikacin-humic acid combination against it.<b>Methods:</b> The combination effect of Amikacin-Humic (AMK-HUM) acid against the highest biofilm-producing <i>A. baumannii</i> SLMK001 was studied via <i>in</i>-<i>vitro</i> (microscopic analysis) and <i>in</i>-<i>silico</i> (Network Pharmacology) analysis.<b>Results:</b> The amikacin-humic acid combination significantly inhibited both the biofilm formation and cell viability of <i>A. baumannii</i> SLMK001. The images observed via Scanning Electron Microscope (SEM) showed a significant decrease in the biofilm matrix. Confocal Laser Scanning Microscope (CLSM) confirmed a reduction of the Z value of its three-dimensional structure. Further, the Network Pharmacology approach supported these experimental findings by identifying the key targets of the amikacin-humic acid combination against the biofilm pathways of <i>A. baumannii</i>.<b>Conclusion:</b> The <i>in-vitro</i> results aligned with the <i>in-silico</i> findings, indicating that the AMK-HUM combination is a promising treatment that significantly activates the key proteins against <i>A. baumannii</i> biofilm formation and pathogenesis.</p>","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":" ","pages":"1573-1585"},"PeriodicalIF":2.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142463284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future microbiologyPub Date : 2024-01-01Epub Date: 2024-10-21DOI: 10.1080/17460913.2024.2412447
Zoozeal Thakur, Renu Chaudhary, Promod K Mehta
{"title":"Deciphering the role of VapBC toxin-antitoxin systems in <i>Mycobacterium tuberculosis</i> stress adaptation.","authors":"Zoozeal Thakur, Renu Chaudhary, Promod K Mehta","doi":"10.1080/17460913.2024.2412447","DOIUrl":"10.1080/17460913.2024.2412447","url":null,"abstract":"<p><p><i>Mycobacterium tuberculosis</i> (<i>Mtb</i>) harbors a high number of Toxin-Antitoxin (TA) systems, wherein half of them belong to virulence associated proteins B and C (VapBC) family that has a characteristic PilT N-terminus domain and ribonuclease activity. Functional insights into <i>Mtb</i> VapBC TA modules unraveled their role in adaptation to various host-mediated stressors, including oxidative/nitrosative, chemical and nutrient starvation as well as multidrug tolerance and establishment of persistence. To understand the intricacies of <i>Mtb</i>'s pathogenesis, absolute cellular targets of 19 VapC(s) were determined. Some exhibit a shared ribonuclease activity, whereas others harbor tRNAse and 23S rRNA cleavage activity. The detailed functional characterization of VapBC4, VapBC12 and VapBC22, including <i>in vivo</i> deletion mutant studies revealed their role in <i>Mtb</i>'s virulence/persistence. For example, the VapC22 mutant was attenuated for <i>Mtb</i>'s growth in mice and elicited a decreased T<sub>H</sub>1 response, whereas mice infected with VapC12 mutant displayed a substantially higher bacillary load and pro-inflammatory response than the wild type, showing a hyper-virulent phenotype. Further experimental studies are needed to decode the functional role of VapBC systems and unravel their cellular targets. Taken together, <i>Mtb</i> VapBC TA systems seem to be promising drug targets owing to their key role in enduring stressors, antibiotic resistance and persistence.</p>","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":" ","pages":"1587-1599"},"PeriodicalIF":2.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142463283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future microbiologyPub Date : 2024-01-01Epub Date: 2024-01-22DOI: 10.2217/fmb-2023-0197
Ignacio Martin-Loeches, Christopher J Bruno, C Andrew DeRyke
{"title":"Perspectives on the use of ceftolozane/tazobactam: a review of clinical trial data and real-world evidence.","authors":"Ignacio Martin-Loeches, Christopher J Bruno, C Andrew DeRyke","doi":"10.2217/fmb-2023-0197","DOIUrl":"10.2217/fmb-2023-0197","url":null,"abstract":"<p><p>Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) are common healthcare-associated infections linked to high morbidity and mortality. Gram-negative pathogens, such as <i>Pseudomonas aeruginosa</i>, exhibit multidrug resistance and are recognized as major public health concerns, particularly among critically ill patients with HABP/VABP. Ceftolozane/tazobactam is a novel combination antibacterial agent comprising ceftolozane (a potent antipseudomonal cephalosporin) and tazobactam (a β-lactamase inhibitor). Phase III trials have demonstrated non-inferiority of ceftolozane/tazobactam to comparators, leading to the approval of ceftolozane/tazobactam for the treatment of complicated urinary tract infections, complicated intra-abdominal infections, and nosocomial pneumonia. In this article, we review the clinical trial evidence and key real-world effectiveness data of ceftolozane/tazobactam for the treatment of serious healthcare-associated Gram-negative infections, focusing on patients with HABP/VABP.</p>","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":" ","pages":"465-480"},"PeriodicalIF":2.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11216532/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139511899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future microbiologyPub Date : 2024-01-01Epub Date: 2024-01-31DOI: 10.2217/fmb-2023-0103
Abdel-Moniem S Hassan, Abdo A Elfiky, Alaa M Elgohary
{"title":"Triple <i>in silico</i> targeting of IMPDH enzyme and RNA-dependent RNA polymerase of both SARS-CoV-2 and <i>Rhizopus oryzae</i>.","authors":"Abdel-Moniem S Hassan, Abdo A Elfiky, Alaa M Elgohary","doi":"10.2217/fmb-2023-0103","DOIUrl":"10.2217/fmb-2023-0103","url":null,"abstract":"<p><p><b>Aim:</b> Mucormycosis has been associated with SARS-CoV-2 infections during the last year. The aim of this study was to triple-hit viral and fungal RNA-dependent RNA polymerases (RdRps) and human inosine monophosphate dehydrogenase (IMPDH). <b>Materials & methods:</b> Molecular docking and molecular dynamics simulation were used to test nucleotide inhibitors (NIs) against the RdRps of SARS-CoV-2 and <i>Rhizopus oryzae</i> RdRp. These same inhibitors targeted IMPDH. <b>Results:</b> Four NIs revealed a comparable binding affinity to the two drugs, remdesivir and sofosbuvir. Binding energies were calculated using the most abundant conformations of the RdRps after 100-ns molecular dynamics simulation. <b>Conclusion:</b> We suggest the triple-inhibition potential of four NIs against pathogenic RdRps and IMPDH, which is worth experimental validation.</p>","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":" ","pages":"9-19"},"PeriodicalIF":3.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139642029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}